Breaking News

Metrics Adds Formulation Scientist

February 14, 2013

DeHart to oversee formulation and manufacturingof clinical trial materials

Dr. Michael DeHart has joined Metrics, Inc. as a new formulation scientist. Dr. DeHart will manage all aspects of personnel and operations related to formulating and manufacturing pharmaceutical materials for Phase I-III clinical trials. He is also responsible for scale up and validation of clinical trial materials, and manufacturing and packaging batches under cGMP guidelines. He will supervise technology transfers and serve as the company’s experimental design expert in both formulation development and process optimization.
 
Prior to joining the company, Dr. DeHart worked for several contract pharmaceutical manufacturing companies, where his responsibilities involved reverse engineering and developing analytical methods. Most recently, he was a development scientist at a commercial manufacturing site for Catalent Pharma Solutions, where he facilitated the technology transfer and scale up of solid oral dosage forms.
 

Related Contract Manufacturing:

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research